Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03493464 · ClinicalTrials.gov registry record · Phase 2
BR55 in Characterization of Ovarian Lesions
A Phase 2 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03493464: Clinical Trial Phase 2 study, sponsored by Bracco Diagnostics.
NCT03493464 is a Phase 2 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03493464, a Phase 2 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.
Primary Outcome
BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement=no focal targeted, stationary imaging signal was detectable; weak enhancement=weak focal targeted imaging signal was detectable and considered possibly stationary; strong enhancement=well-defined and strong focal targeted imaging signal was detectable and considered as definitely stationary).
Interventions
- DRUG BR55
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-12-13 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 2 |
Why NCT03493464 stopped before completion
NCT03493464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which BR55 is the first listed.
NCT03493464 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03493464 about?
NCT03493464 is a clinical study titled "BR55 in Characterization of Ovarian Lesions". This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.
What is the current status of trial NCT03493464?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2018-12-13. Estimated completion is 2021-07-31.
What interventions are being tested in trial NCT03493464?
The interventions under investigation include: BR55 (DRUG).
Who is sponsoring clinical trial NCT03493464?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03493464's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy